Last reviewed · How we verify
Hidroxicloroquina
At a glance
| Generic name | Hidroxicloroquina |
|---|---|
| Sponsor | Instituto de Investigación Marqués de Valdecilla |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (PHASE1)
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (PHASE2)
- Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- Hydroxychloroquin (HCQ) in chILD of Genetic Defect (NA)
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (PHASE1)
- Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hidroxicloroquina CI brief — competitive landscape report
- Hidroxicloroquina updates RSS · CI watch RSS
- Instituto de Investigación Marqués de Valdecilla portfolio CI